At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The financing will in part support development of the firm's PI3K inhibitor paxalisib in PIK3CA-mutated brain cancer and HER2-positive breast cancer.

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

This month, the firm also performed a 1-for-15 reverse share split to maintain compliance with Nasdaq listing requirements.